Your browser doesn't support javascript.
loading
First-in-Human Phase I Study of MBC-11, a Novel Bone-Targeted Cytarabine-Etidronate Conjugate in Patients with Cancer-Induced Bone Disease.
Zinnen, Shawn Patrick; Karpeisky, Alexander; Von Hoff, Daniel D; Plekhova, Larisa; Alexandrov, Alexander.
  • Zinnen SP; MBC Pharma Inc., Aurora, Colorado, USA szinnen@mbcpharma.com.
  • Karpeisky A; MBC Pharma Inc., Aurora, Colorado, USA.
  • Von Hoff DD; Translational Genomics Research Institute (TGEN), Phoenix, Arizona, USA.
  • Plekhova L; Osteros Biomedica Ltd., Moscow, Russia.
  • Alexandrov A; Maxwell Biotech Group, Moscow, Russia.
Oncologist ; 24(3): 303-e102, 2019 03.
Article en En | MEDLINE | ID: mdl-30413669
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Óseas / Ácido Etidrónico / Citarabina / Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Óseas / Ácido Etidrónico / Citarabina / Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Año: 2019 Tipo del documento: Article